SNGX Fundamental Analysis - SOLIGENIX INC

Name: SOLIGENIX INC (SNGX) Stock
Brand: SOLIGENIX INC
Rating: 4 (3 reviews)

Fundamental Rating

SNGX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. SNGX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SNGX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

SNGX had negative earnings in the past year.

SNGX had a negative operating cash flow in the past year.

SNGX had negative earnings in each of the past 5 years.

SNGX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

SNGX has a worse Return On Assets (-184.80%) than 88.95% of its industry peers.

SNGX has a Return On Equity of -582.04%. This is in the lower half of the industry: SNGX underperforms 78.84% of its industry peers.

		Industry Rank	Sector Rank
ROA	-184.8%
ROE	-582.04%
ROIC	N/A

ROA(3y)-83.84%

ROA(5y)-77.43%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SNGX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.

SNGX has more shares outstanding than it did 1 year ago.

The number of shares outstanding for SNGX has been increased compared to 5 years ago.

Compared to 1 year ago, SNGX has an improved debt to assets ratio.

2.2 Solvency

SNGX has an Altman-Z score of -62.57. This is a bad value and indicates that SNGX is not financially healthy and even has some risk of bankruptcy.

SNGX has a worse Altman-Z score (-62.57) than 94.57% of its industry peers.

SNGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-62.57

ROIC/WACCN/A

WACC8.73%

2.3 Liquidity

SNGX has a Current Ratio of 1.47. This is a normal value and indicates that SNGX is financially healthy and should not expect problems in meeting its short term obligations.

SNGX has a Current ratio of 1.47. This is amonst the worse of the industry: SNGX underperforms 81.46% of its industry peers.

SNGX has a Quick Ratio of 1.47. This is a normal value and indicates that SNGX is financially healthy and should not expect problems in meeting its short term obligations.

With a Quick ratio value of 1.47, SNGX is not doing good in the industry: 80.90% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.47
Quick Ratio	1.47

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

SNGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.57%, which is quite impressive.

The Revenue for SNGX has decreased by -100.00% in the past year. This is quite bad

Measured over the past years, SNGX shows a very negative growth in Revenue. The Revenue has been decreasing by -51.88% on average per year.

EPS 1Y (TTM)63.57%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%37.4%

Revenue 1Y (TTM)-100%

Revenue growth 3Y-47.39%

Revenue growth 5Y-51.88%

Sales Q2Q%-100%

3.2 Future

SNGX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.16% yearly.

Based on estimates for the next years, SNGX will show a small growth in Revenue. The Revenue will grow by 6.88% on average per year.

EPS Next Y53.09%

EPS Next 2Y32.34%

EPS Next 3Y21.16%

EPS Next 5YN/A

Revenue Next Year-100%

Revenue Next 2Y10.5%

Revenue Next 3Y6.88%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNGX. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNGX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

SNGX's earnings are expected to grow with 21.16% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y32.34%

EPS Next 3Y21.16%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for SNGX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SOLIGENIX INC

NASDAQ:SNGX (10/29/2025, 12:34:57 PM)

1.5463

-0.01 (-0.88%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-14 2025-08-14/bmo

Earnings (Next)11-06 2025-11-06

Inst Owners4.48%

Inst Owner Change0%

Ins Owners0.01%

Ins Owner Change0.5%

Market Cap12.94M

Revenue(TTM)N/A

Net Income(TTM)-10645600

Analysts82.86

Price Target22.95 (1384.19%)

Short Float %13.02%

Short Ratio0.2

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-21.24%

Min EPS beat(2)-55.11%

Max EPS beat(2)12.62%

EPS beat(4)2

Avg EPS beat(4)-7.57%

Min EPS beat(4)-55.11%

Max EPS beat(4)29.84%

EPS beat(8)5

Avg EPS beat(8)4.34%

EPS beat(12)8

Avg EPS beat(12)-10.32%

EPS beat(16)10

Avg EPS beat(16)-9.11%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)125%

EPS NQ rev (1m)0%

EPS NQ rev (3m)14.62%

EPS NY rev (1m)0%

EPS NY rev (3m)18.55%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	7.08
P/tB	7.08
EV/EBITDA	N/A

EPS(TTM)-3.8

EYN/A

EPS(NY)-1.52

Fwd EYN/A

FCF(TTM)-1.16

FCFYN/A

OCF(TTM)-1.16

OCFYN/A

SpS0

BVpS0.22

TBVpS0.22

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-184.8%
ROE	-582.04%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-83.84%

ROA(5y)-77.43%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score2

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.47
Quick Ratio	1.47
Altman-Z	-62.57

F-Score2

WACC8.73%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)63.57%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%37.4%

EPS Next Y53.09%

EPS Next 2Y32.34%

EPS Next 3Y21.16%

EPS Next 5YN/A

Revenue 1Y (TTM)-100%

Revenue growth 3Y-47.39%

Revenue growth 5Y-51.88%

Sales Q2Q%-100%

Revenue Next Year-100%

Revenue Next 2Y10.5%

Revenue Next 3Y6.88%

Revenue Next 5YN/A

EBIT growth 1Y-49.79%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y11.25%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y11.28%

OCF growth 3YN/A

OCF growth 5YN/A

SOLIGENIX INC / SNGX FAQ

Can you provide the ChartMill fundamental rating for SOLIGENIX INC?

ChartMill assigns a fundamental rating of 2 / 10 to SNGX.

Can you provide the valuation status for SOLIGENIX INC?

ChartMill assigns a valuation rating of 1 / 10 to SOLIGENIX INC (SNGX). This can be considered as Overvalued.

What is the profitability of SNGX stock?

SOLIGENIX INC (SNGX) has a profitability rating of 0 / 10.

What is the expected EPS growth for SOLIGENIX INC (SNGX) stock?

The Earnings per Share (EPS) of SOLIGENIX INC (SNGX) is expected to grow by 53.09% in the next year.

SOLIGENIX INC (SNGX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

SOLIGENIX INC / SNGX FAQ

Can you provide the ChartMill fundamental rating for SOLIGENIX INC?

Can you provide the valuation status for SOLIGENIX INC?

What is the profitability of SNGX stock?

What is the expected EPS growth for SOLIGENIX INC (SNGX) stock?